IMPRESS-Norway About the study

IMPRESS-Norway is a nation-wide study that gives patients personalised treatment with anti-cancer drugs corresponding to their molecular tumour profile rather than the tumour type.

Patients eligible have advanced cancers and have received standard treatment without responding. If the initial molecular screening shows an actionable target for one of the study drugs, they will be assigned to a cohort. Treatment and follow-up will be given according to the prescriptions for the drug. Collection of biopsies and molecular profiling is done at several time points during treatment to monitor response.

The collected data and biobanked material will be used for further translational research such as studies on mechanisms for tumour response and resistance, biomarkers, the utility and reliability of ctDNA in a clinical setting and the use of AI for response evaluation in radiology.

Our lab is responsible for the logistics, processing and biobanking of the IMPRESS-Norway liquid biopsies. We also isolate cell-free DNA from plasma and prepare the ctDNA libraries for targeted sequencing (NGS) as well as the DNA libraries for whole genome sequencing (WGS).